As Sarepta And Valeant Exit Hearings, Biotech Steps Into M&A

It began last Monday in Washington, D.C., with the U.S. Food and Drug Administration’s (FDA) advisory panel convening for 12 hours to make recommendations on Sarepta Therapeutic, Inc.’s controversial drug for a rare form of muscular dystrophy that only strikes young boys, and continued on Wednesday afternoon with a riveting Senate hearing on drug pricing and Valeant Pharmaceuticals VRX -2.13% Then on Wednesday night we had two biotech deals hit the road publicly, with one led by JP Morgan.